The dose for a course of OCS will be according to the participants SoC for OCS use for its NP condition. VAS will be collected daily in morning from screening up to Week 52.The SNOT-22 is a health related quality of life questionnaire and has been shown to be a reliable outcome measure for successful septal surgery and in chronic rhinosinusitis (CRS) management. Participants will receive mepolizumab 100 mg or placebo SC by the investigator or delegate via a pre-filled safety syringe every 4 weeks for 52 weeks. Elsevier Science In the 52-7 days, stage III, multicenter demo, treatment method with the IL-five inhibitor biologic was related with a 57% reduction in the want for surgical Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, Durham SR, Cornet ME, Kariyawasam HH, Gilbert J, Austin D, Maxwell AC, Marshall RP, Fokkens WJ.J Allergy Clin Immunol. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).Each nostril was assessed for polyps and graded at Week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 52. VAS will be collected daily in morning from screening up to Week 52.NP surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (polypectomy) or dilatation of the air passages (e.g. Epub 2006 Sep 26.Drugs R D. 2008;9(2):125-30. doi: 10.2165/00126839-200809020-00006.J Allergy Clin Immunol. Mepolizumab (Nucala), an IL-5 antibody was approved in the past for patients who have severe persistent asthma.A recent study sought to determine whether mepolizumab could reduce the need for surgery in patients with severe recurrent bilateral nasal polyps. For those with nasal polyps, FEV₁ was 326 mL higher (95% CI, 210 - 441), and for those without nasal polyps, it was 235 mL higher (95% CI, 147 - 323). There was a similar study using dupilumab (an anti-IL 4/13 therapy) that also showed improved nasal polyp scores. eCollection 2020.Med Sci Monit. Participants will be asked to rate the severity of their condition on each of the 22 items over the previous 2 weeks using a 6-point rating scale of 0-5 including: 0 = Not present/no problem; 1 = Very mild problem; 2 = Mild or slight problem; 3 = Moderate problem; 4 = Severe problem; 5 = Problem as "bad as it can be". The treatment period will consist of thirteen, 4-weekly doses of mepolizumab or placebo. In the 52-week, phase III, multicenter trial, treatment with the IL-5 inhibitor biologic was associated with a 57% reduction in the need for surgery versus placebo in patients 2017 Oct;140(4):1024-1031.e14. If you suffer from recurrent nasal polyps, have your ENT (Ear, Nose and Throat) doctor coordinate care with your allergy doctor about what the best treatment option is for you. It is also a tool to evaluate outcomes in nasal polyposis. Approximately 400 participants will be randomized (200 participants per treatment arm) in to the study. Perhaps specific biomarkers could be identified.Of note, the patients in this study were not identified with having Samter’s Triad (nasal polyps, asthma, aspirin sensitivity), the management and treatment of these patients could be different.In conclusion, mepolizumab reduced the numbers of patients needing surgery for nasal polyps and improved their nasal polyps overall. COVID-19 is an emerging, rapidly evolving situation. Chronic sinusitis is common, and it can be categorized into 2 types: with nasal polyps and without nasal polyps. Objective: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal … Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. The dose for a course of OCS will be according to the participants SoC for OCS use for its NP condition. Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. Results One hundred five patients received mepolizumab (n = 54) or placebo (n = 51). Please enable it to take advantage of the complete set of features! Various doses of intravenous and oral steroids will be converted to prednisolone-equivalent OCS.Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Various doses of intravenous and oral steroids will be converted to prednisolone-equivalent OCS.Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Both severe eosinophilic asthma and nasal polyps have local eosinophilic inflammation. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).Each nostril was assessed for polyps and graded at Week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 52.